What Does Fatty Acid Chain Length Determine? Functional Division of ACSS, ACSM, ACSL, and ACSVL in Metabolic Pathways

Fatty acid chain length affects the choice of activating enzymes, subcellular metabolic pools, and downstream pathway partitioning. Short-chain fatty acids are mainly linked to acetyl-CoA supply and acetylation regulation. Medium-chain fatty acids are more associated with rapid oxidative energy production. Long-chain fatty acids participate in β-oxidation, glycerolipid synthesis, and membrane lipid remodeling. Very-long-chain fatty acids are closely related to peroxisomal metabolism, neural lipids, and skin barrier function.

Keywords: fatty acid chain length; acyl-CoA synthetase; ACSS; ACSM; ACSL; ACSVL; SLC27; acyl-CoA; fatty acid activation; β-oxidation; lipid metabolism

1 Why Fatty Acid Activation Depends on Chain Length

1.1 Acyl-CoA is the entry form of fatty acid metabolism

Before free fatty acids enter most metabolic reactions, they need to be converted into acyl-CoA by acyl-CoA synthetases. This reaction uses fatty acids, ATP, and CoA as substrates and usually proceeds through an acyl-AMP intermediate to generate the corresponding acyl-CoA, enabling fatty acids to be recognized by oxidases, acyltransferases, elongases, desaturases, and lipid synthesis enzymes.

Fatty acids of different chain lengths differ in solubility, membrane association, transport mode, and subcellular distribution, and they are handled by different activating enzyme families. ACSS mainly processes short-chain fatty acids, ACSM preferentially activates medium-chain fatty acids, ACSL mainly participates in long-chain fatty acid activation, and ACSVL/SLC27 is more closely related to the uptake and activation of long-chain to very-long-chain fatty acids.

1.2 Chain length determines more than substrate selection

(1) Metabolic pool allocation

After activation, short-chain fatty acids can form small acyl-CoA molecules such as acetyl-CoA and propionyl-CoA, which enter the TCA cycle, lipid synthesis, or protein acetylation-related processes. Long-chain fatty acids generate long-chain acyl-CoAs, which are more likely to enter β-oxidation, triglyceride synthesis, phospholipid remodeling, or lipid droplet storage.

(2) Subcellular localization

Mitochondria-associated activation is more likely to affect oxidative energy production. Activation around the endoplasmic reticulum and lipid droplets is more likely to affect glycerolipid synthesis, membrane lipid remodeling, and lipid droplet expansion. Nuclear or perinuclear acetyl-CoA production may affect histone acetylation and transcriptional regulation.

(3) Pathological relevance

ACSL4-mediated activation of polyunsaturated fatty acids can increase the pool of PUFA-containing phospholipid substrates, thereby increasing lipid peroxidation and ferroptosis sensitivity. Abnormal very-long-chain fatty acid handling related to SLC27A4 can affect skin barrier lipids. Changes in SLC27A6 are often associated with myocardial fatty acid uptake and lipotoxicity.

Table 1 Fatty Acid Chain Length, Representative Enzyme Families, and Major Metabolic Fates

Fatty Acid Type	Representative Chain Length	Main Activating Enzyme Family	Typical Metabolic Fate	Research Focus
Short-chain fatty acids	C2-C4	ACSS	Acetyl-CoA/propionyl-CoA generation, TCA cycle, acetylation regulation	Acetate utilization, SCFA signaling, epigenetic regulation
Medium-chain fatty acids	C6-C12	ACSM	Mitochondrial β-oxidation, rapid energy supply, exogenous carboxylic acid metabolism	Medium-chain fatty acid oxidation, hepatic and renal metabolism, carboxylic acid substrate activation
Long-chain fatty acids	C12-C20	ACSL	β-oxidation, triglyceride synthesis, phospholipid remodeling, lipid droplet storage	Lipotoxicity, energy metabolism, membrane lipid remodeling
Long-chain polyunsaturated fatty acids	C18-C22 PUFA	ACSL4, ACSL6	PUFA-CoA generation, PUFA-containing phospholipid remodeling	Lipid peroxidation, ferroptosis, neural membrane lipid composition
Very-long-chain fatty acids	C22 and above	ACSVL/SLC27	Peroxisomal metabolism, sphingolipid/ceramide synthesis, barrier lipid formation	VLCFA accumulation, neural lipids, skin barrier

2 ACSS Family: Short-Chain Fatty Acids and Acetyl-CoA Supply

2.1 ACSS1

ACSS1 mainly catalyzes the conversion of acetate to acetyl-CoA, and its function is more closely related to mitochondrial acetate utilization. It can provide substrates for the TCA cycle, energy metabolism, and the local mitochondrial acetyl-CoA pool. During fasting, low glucose supply, tumor metabolic reprogramming, or increased acetate availability, ACSS1 may become an important auxiliary pathway for maintaining mitochondrial acetyl-CoA.

Increased ACSS1 does not equal enhanced long-chain fatty acid oxidation. Interpretation should be combined with acetate tracing, acetyl-CoA levels, TCA cycle intermediates, oxygen consumption rate, and mitochondrial function indicators.

2.2 ACSS2

ACSS2 also catalyzes acetate to acetyl-CoA, but its function is more commonly associated with cytosolic and nuclear acetyl-CoA supply. Cytosolic acetyl-CoA can be used for fatty acid and cholesterol synthesis, while nuclear acetyl-CoA participates in histone acetylation regulation.

In hypoxia, nutrient restriction, tumor metabolism, and acetate-dependent growth models, ACSS2 changes should be analyzed together with nuclear localization, acetate dependence, acetyl-CoA levels, and histone acetylation status.

2.3 ACSS3

ACSS3 is better understood in the context of propionate and short-chain carboxylic acid metabolism. Unlike ACSS1/2, which are more closely related to the acetate-acetyl-CoA axis, ACSS3 can participate in propionate metabolism, partial short-chain acyl-CoA generation, and mitochondria-related metabolism. If the experiment involves mixed treatment with acetate, propionate, and butyrate, the metabolic products of different short-chain fatty acids should be analyzed separately, rather than attributing all short-chain fatty acid effects to ACSS2.

Table 2 Functional Differences among ACSS Family Members

Member	Main Substrate/Product	Main Functional Scenario	Interpretation Focus
ACSS1	Acetate → acetyl-CoA	Mitochondrial acetate utilization, energy metabolism	Focus on TCA cycle and mitochondrial function
ACSS2	Acetate → acetyl-CoA	Cytosolic lipid synthesis, nuclear acetylation regulation	Focus on nuclear localization, histone acetylation, and acetate dependence
ACSS3	Propionate/short-chain carboxylic acid-related acyl-CoA	Short-chain organic acid metabolism, mitochondria-related metabolism	Should not be simply equated with the acetate metabolic functions of ACSS1/2

3 ACSM Family: Medium-Chain Fatty Acids and Mitochondria-Related Activation

3.1 Medium-chain substrate selection and metabolic localization

The ACSM family mainly catalyzes CoA activation of C4-C12 medium-chain fatty acids and some medium-chain carboxylic acids. Common substrates include butyrate, hexanoate, octanoate, decanoate, and certain branched-chain carboxylic acids.

Compared with ACSS, ACSM substrates have longer chain lengths and stronger hydrophobicity. Compared with ACSL, ACSM is more biased toward mitochondrial-related oxidation of medium-chain fatty acids, hepatic and renal carboxylic acid metabolism, and exogenous carboxylic acid handling. Interpretation should be combined with medium-chain acyl-CoAs, acylcarnitines, oxygen consumption rate, and ATP generation. A decrease in free fatty acids alone should not be used to infer enhanced oxidation.

3.2 Functional features of ACSM members

(1) ACSM1/ACSM2

ACSM1 and ACSM2 are often associated with medium-chain fatty acid activation, hepatic and renal metabolism, and mitochondria-related oxidation. In studies of medium-chain fatty acid energy supply, MCT metabolism, or medium-chain carboxylic acid handling, the expression, enzyme activity, and medium-chain acyl-CoA generation of these members can be prioritized.

(2) ACSM3

ACSM3 is often used in studies related to medium-chain fatty acid oxidation and metabolic diseases. Its changes need to be analyzed together with medium-chain acyl-CoA, acylcarnitines, and oxygen consumption rate. Oxidative flux cannot be determined based only on mRNA changes.

(3) ACSM4/ACSM5

ACSM4 and ACSM5 show certain tissue and substrate specificity and can serve as extended indicators in reproductive tissue, hepatic metabolism, or exogenous carboxylic acid handling. The substrate spectra of different ACSM members are not identical, so experimental design should avoid replacing member-specific analysis with “total ACSM expression.”

Table 3 Common Indicator Combinations in ACSM Family Research

Research Purpose	Recommended Indicators	Supplementary Indicators	Interpretation Focus
Medium-chain fatty acid oxidation	ACSM expression, medium-chain acyl-CoA, oxygen consumption rate	Acylcarnitines, ATP, mitochondrial membrane potential	Determine whether the substrate enters mitochondrial oxidation
MCT energy supply research	C8/C10 consumption, ACSM, β-oxidation enzymes	Ketone bodies, TCA intermediates	Distinguish rapid energy supply from lipid storage
Exogenous carboxylic acid metabolism	ACSM member expression, carboxylic acid-CoA products	Metabolite profile, cytotoxicity	Determine whether the carboxylic acid substrate is activated
Hepatic and renal metabolic differences	ACSM1-5 expression profile	Tissue acyl-CoA profile	Member differences are more important than total family abundance

4 ACSL Family: Long-Chain Fatty Acid Activation and Metabolic Partitioning

4.1 ACSL1

ACSL1 mainly catalyzes long-chain fatty acids such as C16 and C18 to generate acyl-CoAs. Its products can enter β-oxidation, triglyceride synthesis, phospholipid synthesis, or lipid droplet storage. Therefore, ACSL1 acts more like an entry node for long-chain fatty acid metabolic partitioning.

In the liver, myocardium, skeletal muscle, and adipose tissue, ACSL1 changes are often associated with high-fat load, insulin resistance, lipotoxicity, and energy metabolism. If ACSL1 elevation is accompanied by increased lipid droplets, fatty acids may be more biased toward storage. If it is accompanied by increased oxygen consumption rate and acylcarnitines, enhanced β-oxidation is more strongly supported.

4.2 ACSL3

ACSL3 is closely related to the endoplasmic reticulum, lipid droplet formation, and membrane lipid synthesis. After activation by ACSL3, long-chain fatty acids can enter triglyceride, cholesteryl ester, and phospholipid synthesis pathways.

In fatty acid overload, tumor cell lipid reprogramming, or lipid droplet expansion models, ACSL3 should be interpreted together with lipid droplet staining, TAG content, cholesteryl esters, phospholipid profiles, and ER lipid metabolism indicators. It should not be used as a single marker of enhanced fatty acid oxidation.

4.3 ACSL4

ACSL4 is functionally important for polyunsaturated fatty acids such as arachidonic acid and adrenic acid. It promotes PUFA-CoA generation and drives these acyl chains into membrane phospholipid remodeling. ACSL4 does not directly generate reactive oxygen species. Its key role is to expand the oxidizable lipid substrate pool.

When GPX4 function decreases, GSH is insufficient, or iron loading increases, ACSL4-mediated PUFA-PL accumulation is more likely to convert into lipid peroxidation injury. In ferroptosis research, GPX4, SLC7A11, GSH, lipid ROS, and 4-HNE should be detected together.

4.4 ACSL5

ACSL5 participates in long-chain fatty acid activation and is commonly studied in the liver, intestine, and mitochondria-related metabolism. In intestinal samples, ACSL5 changes can be associated with fatty acid absorption and glycerolipid resynthesis. In liver or muscle samples, CPT1, ACAD, acylcarnitines, and oxygen consumption rate should be combined to determine whether fatty acids are biased toward oxidative energy production.

The metabolic direction of ACSL5 differs substantially among tissues, and the same interpretation should not be applied across different tissue contexts.

4.5 ACSL6

ACSL6 is more often studied in the nervous system, hematopoietic system, and PUFA-rich tissues. It is commonly associated with DHA, AA, and other PUFA utilization and membrane phospholipid composition regulation.

Unlike ACSL4, which is more closely associated with ferroptosis sensitivity, ACSL6 is better analyzed from the perspectives of neural membrane lipids, synaptic function, myelin lipids, and cell differentiation. When studying ACSL6, DHA- or AA-containing phospholipid molecular species should be prioritized over total fatty acid content alone.

Table 4 Functional Division of ACSL Family Members

Member	Main Functional Tendency	Typical Research Scenario	Recommended Combined Indicators
ACSL1	Partitioning of long-chain fatty acid oxidation and storage	Liver, myocardium, skeletal muscle, adipose tissue	OCR, acylcarnitines, TAG, lipid droplets
ACSL3	Lipid droplet formation, glycerolipid and membrane lipid synthesis	Lipid droplet expansion, tumor lipid metabolism, ER lipid remodeling	TAG, cholesteryl esters, phospholipid profile, lipid droplet markers
ACSL4	PUFA activation, lipid peroxidation sensitivity	Ferroptosis, inflammatory lipids, membrane lipid oxidation	PUFA-PL, lipid ROS, GPX4, GSH, 4-HNE
ACSL5	Long-chain fatty acid oxidation/absorption/storage	Intestinal absorption, hepatic metabolism, energy metabolism	CPT1, ACAD, acylcarnitines, TAG
ACSL6	PUFA membrane lipid composition regulation	Nervous system, hematopoietic system, DHA/AA lipid remodeling	DHA/AA phospholipids, lipidomics, neurological functional indicators

5 ACSVL/SLC27 Family: Very-Long-Chain Fatty Acids, Uptake, and Complex Lipid Synthesis

5.1 Relationship between ACSVL and SLC27/FATP

ACSVL is often used interchangeably with the SLC27/FATP nomenclature system. Representative members include SLC27A1-FATP1, SLC27A2-FATP2, SLC27A3-FATP3, SLC27A4-FATP4, SLC27A5-FATP5, and SLC27A6-FATP6.

This family not only participates in long-chain to very-long-chain fatty acid activation but is also commonly associated with fatty acid transmembrane uptake, peroxisomal metabolism, and complex lipid synthesis. Therefore, research should distinguish between “enhanced uptake” and “enhanced activation.”

5.2 Functional division of representative members

(1) SLC27A1/FATP1

SLC27A1 is often associated with fatty acid uptake, adipose tissue, and muscle lipid utilization. In insulin resistance, muscle fatty acid oxidation, and adipose tissue lipid storage studies, SLC27A1 changes may reflect altered exogenous fatty acid entry into cells. However, acyl-CoA, lipid droplets, and oxidative readouts are still needed to determine metabolic fate.

(2) SLC27A2/FATP2

SLC27A2 has long-chain and very-long-chain fatty acid activating capacity and is strongly associated with liver, kidney, and peroxisome-related metabolism. Very-long-chain fatty acids usually need to be activated into VLCFA-CoA before entering peroxisomal β-oxidation. Therefore, SLC27A2 should be interpreted together with VLCFA-CoA, peroxisomal β-oxidation, and hepatic/renal lipid metabolism indicators.

(3) SLC27A3/FATP3

SLC27A3 is less extensively studied and is often linked to tissue development, vascular-related processes, and membrane lipid metabolism. Its functional interpretation depends on specific tissue and model context and is best supported by lipidomics and member-specific intervention.

(4) SLC27A4/FATP4

SLC27A4 is closely related to skin barrier function, intestinal lipid absorption, and very-long-chain fatty acid metabolism. In studies of stratum corneum lipids, ceramide synthesis, and barrier dysfunction, SLC27A4 should be analyzed together with VLCFA, ceramide molecular species, and barrier function indicators.

(5) SLC27A5/FATP5

SLC27A5 is mainly associated with hepatic fatty acid uptake, long-chain fatty acid activation, and bile acid-related metabolism. In fatty liver disease, bile acid metabolic disorders, and hepatic lipid homeostasis research, SLC27A5 can be analyzed together with hepatic lipid deposition, acyl-CoA profiles, and bile acid metabolism.

(6) SLC27A6/FATP6

SLC27A6 is commonly studied in myocardial fatty acid uptake and energy metabolism. The myocardium highly depends on fatty acids for energy production, and abnormal SLC27A6 may affect fatty acid uptake, lipotoxicity, and energy metabolic balance. In myocardial models, oxygen consumption rate, lipid droplets, myocardial function, and long-chain acyl-CoA changes should be analyzed together.

Table 5 Functional Positioning of ACSVL/SLC27 Family Members

Member	Common Name	Main Functional Direction	Typical Sample or Scenario	Interpretation Focus
SLC27A1	FATP1	Fatty acid uptake, long-chain fatty acid utilization	Adipose tissue, skeletal muscle	Distinguish increased uptake from enhanced oxidation
SLC27A2	FATP2/ACSVL1	Long-chain/very-long-chain fatty acid activation, peroxisome-related metabolism	Liver, kidney	Focus on VLCFA-CoA and peroxisomal function
SLC27A3	FATP3	Tissue-specific lipid metabolism	Developmental, vascular, membrane lipid research	Interpretation requires specific model context
SLC27A4	FATP4	Very-long-chain fatty acid handling, barrier lipid synthesis	Skin, intestine	Focus on ceramides and skin barrier lipids
SLC27A5	FATP5	Hepatic fatty acid uptake, bile acid-related metabolism	Liver, fatty liver models	Combine with hepatic lipid deposition and bile acid metabolism
SLC27A6	FATP6	Myocardial fatty acid uptake and utilization	Myocardium, myocardial metabolic models	Focus on myocardial lipotoxicity and energy metabolism

6 How Fatty Acid Chain Length Affects Metabolic Pathway Selection

6.1 Short-chain fatty acids

Short-chain fatty acids can originate from gut microbial fermentation, cellular metabolism, or exogenous supplementation. After acetate is converted to acetyl-CoA by ACSS1/2, it can enter the TCA cycle, lipid synthesis, or nuclear acetylation regulation. Propionate-related metabolism can connect propionyl-CoA, succinyl-CoA, and organic acid metabolism.

Short-chain fatty acid research should distinguish three types of effects: energy substrate supply, carbon source supplementation, and signaling regulation. The localization of ACSS members often explains functional differences better than total expression.

6.2 Medium-chain fatty acids

Medium-chain fatty acids are relatively easy to oxidize and utilize and are commonly studied in nutritional intervention, rapid energy supply, and metabolic stress research. ACSM-mediated medium-chain fatty acid activation can promote β-oxidation, but this process is still limited by mitochondrial function, CoA supply, NAD⁺/FAD regeneration, and downstream oxidative capacity.

If cell energy status improves after medium-chain fatty acid treatment, oxygen consumption rate, ATP, acylcarnitines, and mitochondrial function should be combined to distinguish true enhanced energy production from metabolic adaptation.

6.3 Long-chain fatty acids

After activation by the ACSL family, long-chain fatty acids can enter multiple competing pathways. When entering mitochondria-related pathways, long-chain acyl-CoAs need to participate in β-oxidation through the carnitine shuttle system. When entering ER- and lipid droplet-related pathways, they can be used for triglyceride, cholesteryl ester, and phospholipid synthesis.

The metabolic consequences of palmitate, oleate, arachidonic acid, and DHA treatment models are not the same. They should be analyzed separately according to substrate saturation, chain length, and downstream lipid molecular species.

6.4 Very-long-chain fatty acids

Very-long-chain fatty acid metabolism is closely associated with peroxisomes, neural lipids, sphingolipids, skin barrier function, and complex membrane lipid composition. Abnormal very-long-chain fatty acid uptake and activation mediated by the ACSVL/SLC27 family may cause VLCFA accumulation, altered ceramide profiles, or decreased tissue barrier function.

In very-long-chain fatty acid research, VLCFA-CoA, C24-C26 fatty acids, ceramide molecular species, and peroxisomal β-oxidation capacity provide more interpretive value than total fatty acids.

Table 6 Experimental Design Focus for Fatty Acids of Different Chain Lengths

Fatty Acid Chain Length	Common Treatment Substrates	Key Enzyme Family	Key Readouts	Common Pitfall
Short-chain	Acetate, propionate, butyrate	ACSS	Acetyl-CoA, propionyl-CoA, histone acetylation, TCA tracing	Looking only at total acetyl-CoA without distinguishing cytosolic/nuclear/mitochondrial sources
Medium-chain	Hexanoate, octanoate, decanoate	ACSM	Medium-chain acyl-CoA, acylcarnitines, OCR, ATP	Directly equating fatty acid consumption with enhanced oxidation
Long-chain saturated/monounsaturated	Palmitate, stearate, oleate	ACSL1/3/5	Long-chain acyl-CoA, TAG, lipid droplets, β-oxidation indicators	Not distinguishing oxidation, storage, and lipotoxicity
Long-chain polyunsaturated	Arachidonic acid, DHA, adrenic acid	ACSL4/6	PUFA-CoA, PUFA-PL, lipid ROS	Measuring only ACSL4 expression without detecting lipid peroxidation
Very-long-chain	C22-C26 fatty acids	ACSVL/SLC27	VLCFA, VLCFA-CoA, ceramides, peroxisomal function	Replacing VLCFA molecular species analysis with total fatty acids

7 Detection Methods and Result Interpretation

7.1 Expression detection

qPCR and Western blot are suitable for analyzing expression changes in ACSS, ACSM, ACSL, and SLC27 members, but they cannot independently prove metabolic flux. Homology exists among family members, and antibody specificity and primer cross-amplification are common risks. If a specific isoenzyme is being studied, siRNA, overexpression, knockout cells, or negative control samples should be used to validate the detection system.

7.2 Acyl-CoA profile detection

The acyl-CoA profile is a core metabolic readout for determining acyl-CoA synthetase function. LC-MS can distinguish acetyl-CoA, propionyl-CoA, medium-chain acyl-CoA, long-chain acyl-CoA, and very-long-chain acyl-CoA. Sample handling requires rapid quenching at low temperature to avoid acyl-CoA hydrolysis or secondary changes during extraction.

7.3 Isotope tracing

Stable isotope tracing can determine which pathway fatty acids enter after activation. ^13C-acetate can be used for ACSS-related acetyl-CoA and histone acetylation research. ^13C-palmitate can be used for ACSL-related β-oxidation, TAG synthesis, and acylcarnitine analysis. ^13C-arachidonic acid or ^13C-DHA can be used for ACSL4/6-related membrane lipid remodeling analysis.

7.4 Functional readouts

Fatty acid oxidation can be evaluated by oxygen consumption rate, acylcarnitines, ketone bodies, and TCA intermediates. Lipid storage can be evaluated by TAG, lipid droplet staining, and glycerolipid profiles. Membrane lipid remodeling can be evaluated by phospholipid molecular species. Lipid peroxidation can be evaluated by lipid ROS, MDA, 4-HNE, and GPX4 functional status. Expression, metabolites, and functional readouts should be interpreted as an integrated set.

Table 7 Common Problems and Optimization Directions in Acyl-CoA Synthetase Research

Problem	Possible Cause	Optimization Direction
mRNA increases but acyl-CoA does not increase	Insufficient substrate, insufficient CoA, protein not upregulated, or enzyme activity limited	Add protein detection, acyl-CoA profiling, and substrate supplementation experiments
Fatty acid uptake increases but oxidation does not increase	Fatty acids enter storage or membrane lipid synthesis pathways	Combine TAG, phospholipids, OCR, and acylcarnitine detection
ACSL4 increases but ferroptosis is not obvious	PUFA substrate is insufficient, or GPX4/GSH still buffers lipid peroxidation	Detect PUFA-PL, lipid ROS, GPX4, and GSH
VLCFA accumulates but SLC27 does not change obviously	Peroxisomal oxidation is limited or downstream metabolism is blocked	Detect peroxisomal β-oxidation and VLCFA-CoA
Antibody results are inconsistent with metabolic results	Poor antibody specificity, localization changes, or post-translational regulation	Use knockdown/knockout validation and add localization experiments
The same ACS member shows opposite results in different tissues	Tissue metabolic background differs	Interpret by tissue separately and avoid applying the same conclusion across tissues

8 Product Selection for Fatty Acid Chain Length Specificity and ACS Family Research

Table 8 Product Selection for ACS Family Expression Intervention, Protein Validation, and Functional Regulation

Application Module	Cat. No.	Product Name	Grade & Purity	Application Positioning
ACSS short-chain fatty acid activation	A1490832	ACSS1 Human Pre-designed siRNA Set A		Used for ACSS1 knockdown to validate the role of acetate entering mitochondrial acetyl-CoA and energy metabolism
ACSS short-chain fatty acid activation	A1477391	ACSS2 Human Pre-designed siRNA Set A		Used for ACSS2 knockdown to analyze acetate-dependent acetyl-CoA generation, lipid synthesis, and nuclear acetylation regulation
ACSS short-chain fatty acid activation	A1423677	ACSS2-IN-1		Used for ACSS2 functional inhibition to validate acetate utilization and ACSS2-dependent metabolic pathways
ACSS short-chain fatty acid activation	A1491148	ACSS3 Human Pre-designed siRNA Set A		Used for ACSS3 knockdown to study propionate and short-chain carboxylic acid-related acyl-CoA generation
ACSS short-chain fatty acid activation	Ab325831	Recombinant ACSS2 Antibody	KD Validation	Used for ACSS2 protein expression validation; suitable for ACSS2 knockdown or inhibition models
ACSS short-chain fatty acid activation	P743593	pLenti-ACSS3-sgRNA		Used as a negative control for ACSS3 protein detection and antibody validation
ACSS short-chain fatty acid activation	P743594	pLenti-ACSS3-sgRNA		Used as a negative control for ACSS3 transcription detection and qPCR method validation
ACSM medium-chain fatty acid activation	A1489729	ACSM1 Human Pre-designed siRNA Set A		Used for ACSM1 knockdown to study medium-chain fatty acid activation and mitochondria-related oxidation
ACSM medium-chain fatty acid activation	A1475269	ACSM2A Human Pre-designed siRNA Set A		Used for ACSM2A knockdown to analyze medium-chain carboxylic acid substrate handling and hepatic/renal metabolism
ACSM medium-chain fatty acid activation	A1461093	ACSM3 Human Pre-designed siRNA Set A		Used for ACSM3 knockdown to validate medium-chain acyl-CoA generation and oxidative flux changes
ACSM medium-chain fatty acid activation	A1483204	ACSM4 Human Pre-designed siRNA Set A		Used for ACSM4 functional validation; suitable for tissue-specific medium-chain carboxylic acid metabolism studies
ACSM medium-chain fatty acid activation	A1481566	ACSM5 Human Pre-designed siRNA Set A		Used for ACSM5 knockdown to analyze medium-chain substrate activation and exogenous carboxylic acid metabolism
ACSM medium-chain fatty acid activation	P743591	pLenti-ACSM5-sgRNA		Used as a negative control for ACSM5 protein detection and antibody validation
ACSM medium-chain fatty acid activation	P743592	pLenti-ACSM5-sgRNA		Used as a negative control for ACSM5 transcription detection and qPCR validation
ACSL long-chain fatty acid activation	A1480269	ACSL1 Human Pre-designed siRNA Set A		Used for ACSL1 knockdown to distinguish long-chain fatty acid partitioning into β-oxidation or triglyceride storage
ACSL long-chain fatty acid activation	A1490823	ACSL3 Human Pre-designed siRNA Set A		Used for ACSL3 knockdown to study lipid droplet formation, ER lipid metabolism, and membrane lipid synthesis
ACSL long-chain fatty acid activation	A1490354	ACSL4 Human Pre-designed siRNA Set A		Used for ACSL4 knockdown to validate PUFA activation, lipid peroxidation, and ferroptosis sensitivity
ACSL long-chain fatty acid activation	A1480010	ACSL5 Human Pre-designed siRNA Set A		Used for ACSL5 knockdown to study intestinal lipid absorption, hepatic lipid metabolism, and long-chain fatty acid oxidation
ACSL long-chain fatty acid activation	A1480849	ACSL6 Human Pre-designed siRNA Set A		Used for ACSL6 knockdown to analyze DHA/AA and other PUFA membrane lipid composition regulation
ACSL long-chain fatty acid activation	A1490152	Acsl1 Mouse Pre-designed siRNA Set A		Used for mouse Acsl1 knockdown models; suitable for fatty acid oxidation and storage partitioning in animal-derived cells
ACSL long-chain fatty acid activation	A1490801	Acsl4 Rat Pre-designed siRNA Set A		Used for rat Acsl4 knockdown models; suitable for lipid peroxidation and ferroptosis-related research
ACSL long-chain fatty acid activation	A1490163	Acsl5 Mouse Pre-designed siRNA Set A		Used for mouse Acsl5 knockdown models to analyze intestinal, hepatic, or muscle lipid metabolism
ACSL long-chain fatty acid activation	Ab327263	Recombinant ACSL4 Antibody	KD Validation	Used for ACSL4 protein expression validation; suitable for ACSL4 knockdown and ferroptosis models
ACSL long-chain fatty acid activation	EJ1515058	Human Long-chain-fatty-acid—CoA Ligase 4 (ACSL4) ELISA Kit	BioReagent	Used for ACSL4 quantification in human samples and auxiliary analysis of PUFA activation and lipid peroxidation risk
ACSVL/SLC27 fatty acid uptake and VLCFA activation	S1490221	SLC27A1 Human Pre-designed siRNA Set A		Used for SLC27A1/FATP1 knockdown to study fatty acid uptake and lipid utilization in muscle/adipose tissue
ACSVL/SLC27 fatty acid uptake and VLCFA activation	S1477777	SLC27A2 Human Pre-designed siRNA Set A		Used for SLC27A2/FATP2 knockdown to analyze long-chain/very-long-chain fatty acid activation and peroxisomal metabolism
ACSVL/SLC27 fatty acid uptake and VLCFA activation	S1485362	SLC27A3 Human Pre-designed siRNA Set A		Used for SLC27A3/FATP3 knockdown to study tissue-specific lipid metabolism and membrane lipid remodeling
ACSVL/SLC27 fatty acid uptake and VLCFA activation	S1463578	SLC27A4 Human Pre-designed siRNA Set A		Used for SLC27A4/FATP4 knockdown to analyze very-long-chain fatty acid handling, ceramide synthesis, and skin barrier lipids
ACSVL/SLC27 fatty acid uptake and VLCFA activation	S1463544	SLC27A5 Human Pre-designed siRNA Set A		Used for SLC27A5/FATP5 knockdown to study hepatic fatty acid uptake and bile acid-related metabolism
ACSVL/SLC27 fatty acid uptake and VLCFA activation	Ab127915	SLC27A5/BAL Antibody	See COA	Used for SLC27A5 protein expression validation; suitable for hepatic lipid metabolism research
ACSVL/SLC27 fatty acid uptake and VLCFA activation	S1482543	SLC27A6 Human Pre-designed siRNA Set A		Used for SLC27A6/FATP6 knockdown to study myocardial fatty acid uptake and energy metabolism
ACSVL/SLC27 fatty acid uptake and VLCFA activation	S1490813	Slc27a1 Mouse Pre-designed siRNA Set A		Used for mouse Slc27a1 knockdown; suitable for adipose tissue and skeletal muscle lipid metabolism models
FATP1 functional regulation	F655352	FATP1-IN-1	Moligand™, 10 mM in DMSO	Used for inhibition of FATP1-mediated fatty acid uptake and activation pathways
FATP1 functional regulation	F609337	FATP1-IN-1	Moligand™, ≥98%	Used for FATP1 functional inhibition and dose-response studies
FATP1 functional regulation	F649908	FATP1-IN-2	≥98%	Used to validate FATP1-related fatty acid uptake, long-chain fatty acid utilization, and lipotoxicity changes
FATP1 functional regulation	F656051	FATP1-IN-2	10 mM in DMSO	Used for cell treatment and FATP1 inhibition model establishment
Acyl-CoA generation system	A774049	Acyl-CoA Synthetase (ACS)	Bioactive, ActiBioPure™, high performance, EnzymoPure™, ≥85% (SDS-PAGE), ≥5 U/mg protein	Used for fatty acid CoA activation reactions, enzyme activity system validation, and positive controls
Acyl-CoA generation system	R1506902	Acyl-CoA Synthetase (ACS)	Bioactive, Recombinant, ActiBioPure™, high performance, EnzymoPure™, ≥1 U/mg enzyme powder	Used for in vitro acyl-CoA generation system establishment and substrate activation validation
Acyl-CoA generation system	R1507820	Acyl-CoA Synthetase (ACS)	Bioactive, Recombinant, ActiBioPure™, high performance, EnzymoPure™, ≥90% (SDS-PAGE), ≥4 U/mg enzyme powder; ≥30 U/mg protein	Used for fatty acid chain-length substrate activation, ACS enzymatic reactions, and method optimization

Table 9 Product Selection for Fatty Acid Substrates, Metabolic Standards, and Lipid Flux Readouts

Application Module	Cat. No.	Product Name	Grade & Purity	Application Positioning
Fatty acid uptake and tracing	B744202	BODIPY 500/510 C1, C12 (Fatty Acid Green Fluorescence Probe)		Used for fatty acid uptake, intracellular fatty acid transport, and FATP/SLC27-related functional detection
Fatty acid substrate supplementation	F196323	Fatty acids, C14-18 and C16-18-unsatd., sodium salts	≥90%	Used for long-chain unsaturated fatty acid supplementation, ACSL-related substrate utilization, and membrane lipid remodeling studies
Fatty acid substrate supplementation	F485429	Fatty Acid Supplement	Animal Free, for cell culture, liquid,sterile-filtered	Used for cellular fatty acid supply and lipid metabolism model establishment
Fatty acid profile analysis	S475286	Soya-maize oil blend (fatty acid profile)	analytical standard, BCR®	Used for fatty acid composition analysis, GC/LC method calibration, and complex fatty acid profile validation
Fatty acid profile analysis	F693407	Fatty acids， C16-18 and C18-unsatd.， Me esters	AR	Used for fatty acid methyl ester analysis and GC method establishment
Fatty acid profile analysis	F477511	Fatty Acid Ethyl Esters (FAEES), C4 - C24 Even Carbon Saturated	analytical standard, 1000μg/mL each component in hexane	Used for C4-C24 chain-length fatty acid derivative analysis
Fatty acid profile analysis	F485861	Fatty Acid Metabolite Library of Standards		Used for fatty acid metabolite identification, lipidomics, and chain-length distribution analysis
Fatty acid profile analysis	S405929	Standard Mixture of Fatty Acid Methyl Esters (consists of Methyl Hexanoate, Heptanoate, Octanoate, Nonanoate, and Decanoate) [Standard Material for GC]		Used for C6-C10 medium-chain fatty acid GC analysis and ACSM substrate-related research
Fatty acid profile analysis	S405927	Standard Mixture of Fatty Acid Methyl Esters (consists of Methyl Decanoate, Laurate, Myristate, Palmitate and Stearate) [Standard Material for GC]		Used for C10-C18 fatty acid chain-length analysis, covering the ACSM/ACSL substrate boundary
Fatty acid profile analysis	F462892	Fatty Acid Methyl Esters, Saturated Straight Chains	analytical standard	Used for saturated fatty acid chain-length distribution and GC quantification
Fatty acid profile analysis	F462894	Fatty Acids, Odd Carbon Straight Chains Kit	analytical standard	Used for odd-chain fatty acid analysis and fatty acid source interpretation
Isotope tracing	A474009	Algal fatty acid mixture-¹³C	≥99 atom% 13C	Used for fatty acid isotope tracing, lipid flux, and membrane lipid remodeling analysis
Omega fatty acid analysis	O475548	Omega-3 and Omega-6 fatty acids in fish oil	NIST®3275	Used for ω-3/ω-6 fatty acid profile analysis and PUFA-related ACSL4/ACSL6 research
Fish oil fatty acid profile	C488090	Cod liver oil fatty acid methyl esters		Used for fish oil fatty acid profile and PUFA composition analysis
Fish oil fatty acid profile	C478517	Cod liver oil fatty acid methyl esters	BioReagent, suitable for insect cell culture	Used for cod liver oil fatty acid composition analysis and PUFA research
Free fatty acid detection	A1492746	Free Fat Acid (FFA) Content Assay Kit (Micro Method)	BioReagent	Used to evaluate fatty acid release, uptake/consumption, and substrate pool changes before ACS activation
Triglyceride storage	T1505523	Triglyceride (TG) Content Assay kit (GPO-PAP, Micro Method)	BioReagent	Used to determine whether long-chain fatty acids enter triglyceride synthesis and lipid droplet storage
Triglyceride storage	T1509111	Triglyceride (TG) Content Detection Kit (Solvent Extraction, Colorimetric Method)	BioReagent	Used for colorimetric detection of triglycerides and auxiliary distinction between fatty acid oxidation and storage partitioning
Lipid droplet staining	S774135	Saturated Oil Red O Staining Solution	BioReagent, Biological Stain, for microscopy	Used for observing lipid droplet accumulation; suitable for ACSL1/3/5-related lipid storage research
Lipid peroxidation	H274882	4-Hydroxynonenal (4-HNE)	Moligand™, ≥97%	Used for lipid peroxidation injury, PUFA oxidation, and ferroptosis-related models
Lipid peroxidation	H425859	4-Hydroxynonenal (4-HNE)	Moligand™, 10mM in DMSO	Used for cellular lipid peroxidation intervention and dose-response experiments
Lipid peroxidation	EJ1515213	4-Hydroxynonenal (4-HNE) ELISA Kit	BioReagent	Used to detect 4-HNE levels in samples and evaluate lipid peroxidation degree
Lipid peroxidation	EJ1515573	Human 4-Hydroxynonenal (4-HNE) ELISA Kit	BioReagent	Used for lipid peroxidation detection in human samples
Lipid peroxidation	EJ1515455	Mouse 4-Hydroxynonenal (4-HNE) ELISA Kit	BioReagent	Used for lipid peroxidation and ferroptosis-related detection in mouse models
Acylcarnitine profile	R355659	(R)-Butyryl Carnitine Chloride	≥95%	Used for short-chain fatty acid oxidation and acylcarnitine profile analysis
Acylcarnitine profile	H757878	DL-Hexanoyl carnitine-d3 hydrochloride	CP≥96%, ≥98 atom% D	Used for C6 acylcarnitine LC-MS quantification and medium-chain fatty acid oxidation analysis
Acylcarnitine profile	O757645	Octanoyl carnitine-d3 HCl		Used for C8 acylcarnitine quantification and ACSM-related medium-chain oxidative flux evaluation
Acylcarnitine profile	D757868	Decanoyl carnitine-d3 HCl		Used for C10 acylcarnitine quantification and medium-chain fatty acid oxidation evaluation
Acylcarnitine profile	D757866	Dodecanoyl carnitine-d3 HCl		Used for C12 acylcarnitine analysis, covering the medium- to long-chain substrate boundary
Acylcarnitine profile	T757642	Tetradecanoyl carnitine-d3 HCl	Moligand™, ≥98%(CP),≥98 atom% D	Used for C14 acylcarnitine quantification and long-chain fatty acid oxidation analysis
Acylcarnitine profile	P757816	Palmitoyl carnitine-d3 HCl		Used for C16 acylcarnitine quantification; suitable for palmitate oxidation and CPT-related pathway analysis
Acylcarnitine profile	O757847	Octadecanoyl carnitine-d3 HCl		Used for C18 acylcarnitine quantification and stearate oxidation analysis
Acylcarnitine profile	O130781	oleoyl L-carnitine	≥99%	Used for oleate-related fatty acid oxidation and long-chain acylcarnitine profile analysis
Acylcarnitine profile	G1438987	Glutarylcarnitine-dchloride		Used for organic acid metabolism and extended acylcarnitine profile analysis
Acylcarnitine profile	G1440181	Glutarylcarnitine lithium	≥99%	Used for organic acid-related acylcarnitine quantification and β-oxidation abnormality analysis
Fatty acid binding and transport	EJ1514639	Human Fatty Acid Binding Protein 1, Liver (FABP1) ELISA Kit	BioReagent	Used for detecting liver-type fatty acid binding protein in human samples and supporting evaluation of intracellular fatty acid transport
Fatty acid binding and transport	H1509865	Human L-FABP ELISA Kit	BioReagent	Used for hepatic fatty acid binding and transport research
Fatty acid binding and transport	EJ1514649	Human Fatty Acid Binding Protein 2, Intestinal (FABP2) ELISA Kit	BioReagent	Used for intestinal fatty acid absorption and intracellular transport detection
Fatty acid binding and transport	H1509982	Human FABP2/I-FABP ELISA Kit	BioReagent	Used for human FABP2 detection and auxiliary analysis of intestinal lipid absorption
Fatty acid binding and transport	EJ1514751	Human Fatty Acid Binding Protein 4, Adipocyte (FABP4) ELISA Kit	BioReagent	Used for adipocyte fatty acid binding, adipose tissue metabolism, and insulin resistance research
Fatty acid binding and transport	EJ1514753	Human Fatty Acid Binding Protein 5, Epidermal (FABP5) ELISA Kit	BioReagent	Used for intracellular fatty acid transport, inflammatory lipids, and epidermal lipid metabolism research
Fatty acid binding and transport	EJ1512787	Mouse Fatty Acid Binding Protein 3, Muscle And Heart (FABP3) ELISA Kit	BioReagent	Used for mouse myocardial fatty acid utilization and myocardial energy metabolism research
Fatty acid binding and transport	M1510086	Mouse L-FABP ELISA Kit	BioReagent	Used for mouse hepatic fatty acid binding and transport detection
Fatty acid binding and transport	EJ1513082	Mouse Fatty Acid Binding Protein 1 (LFABP) ELISA Kit	BioReagent	Used for mouse hepatic lipid metabolism and fatty acid transport research
Fatty acid binding and transport	EJ1513139	Mouse Fatty Acid Binding Protein 2, Intestinal (FABP2) ELISA Kit	BioReagent	Used for mouse intestinal fatty acid absorption and transport analysis
Fatty acid synthesis background	EJ1514752	Human Fatty Acid Synthase (FASN) ELISA Kit	BioReagent	Used to distinguish fatty acid activation from changes in de novo fatty acid synthesis background
Fatty acid synthesis background	EJ1513138	Mouse Fatty Acid Synthase (FASN) ELISA Kit	BioReagent	Used to detect fatty acid synthesis background in mouse samples
Fatty acid synthesis background	F1516011	Fatty Acid Synthase (FAS) Activity Assay Kit (UV Micro Method)	BioReagent	Used to detect de novo fatty acid synthesis activity and support lipid metabolism pathway partitioning analysis
Fatty acid synthesis background	F1516012	Fatty Acid Synthase (FAS) Activity Assay Kit (UV Colorimetric Method)	BioReagent	Used for colorimetric detection of FAS activity and auxiliary lipid metabolism pathway partitioning analysis
Fatty acid desaturation background	T286634	T 3364366	≥98%(HPLC)	Used for regulation of polyunsaturated fatty acid generation and membrane lipid remodeling background
Fatty acid desaturation background	M127205	MK-8245	≥98%	Used to analyze monounsaturated fatty acid generation, lipid droplet storage, and lipotoxicity background

9 Common Questions

9.1 What are the main differences among ACSS, ACSM, ACSL, and ACSVL?

The main differences lie in substrate chain-length preference, subcellular localization, and downstream metabolic direction. ACSS preferentially handles short-chain fatty acids, ACSM preferentially handles medium-chain fatty acids, ACSL preferentially handles long-chain fatty acids, and ACSVL/SLC27 is more associated with long-chain to very-long-chain fatty acid uptake and activation.

9.2 Why is ACSL4 commonly used in ferroptosis research?

ACSL4 promotes polyunsaturated fatty acid activation and drives these fatty acids into membrane phospholipid remodeling. PUFA-containing phospholipids are more prone to peroxidation. When GPX4 or the GSH system is insufficient, cellular lipid peroxidation and ferroptosis sensitivity increase.

9.3 Does increased ACSL1 necessarily indicate enhanced fatty acid oxidation?

No. Long-chain acyl-CoAs generated by ACSL1 can enter β-oxidation, triglyceride storage, or membrane lipid synthesis. Oxygen consumption rate, acylcarnitines, TAG, and lipid droplet indicators are needed to determine metabolic fate.

9.4 What is the relationship between ACSVL and FATP?

ACSVL is often used interchangeably with the SLC27/FATP family nomenclature. This family is not only associated with long-chain/very-long-chain fatty acid activation but also participates in fatty acid uptake. Therefore, both transport and activation functions should be considered in research.

9.5 Is qPCR alone sufficient for studying fatty acid chain-length specificity?

No. qPCR only indicates transcriptional changes and cannot prove substrate activation or entry into a specific metabolic pathway. A more reliable design should include protein detection, acyl-CoA profiling, isotope tracing, lipidomics, and functional readouts.

9.6 Why is ACSM more relevant for medium-chain fatty acid research?

Medium-chain fatty acids are relatively easy to enter mitochondrial oxidative energy production, and the ACSM family has strong relevance to medium-chain fatty acids and some medium-chain carboxylic acids. In studies of medium-chain fatty acid energy supply, MCT metabolism, or medium-chain carboxylic acid handling, ACSM is more targeted than ACSL.

9.7 Why should peroxisomes be considered in very-long-chain fatty acid research?

Very-long-chain fatty acids usually require initial β-oxidation in peroxisomes. After ACSVL/SLC27 participates in very-long-chain fatty acid uptake and activation, impaired peroxisomal function may lead to VLCFA accumulation and affect neural lipids, skin barrier function, and complex membrane lipid homeostasis.

Fatty acid chain length determines the choice of activating enzymes, subcellular metabolic pools, and downstream pathway partitioning. ACSS connects short-chain fatty acids with acetyl-CoA supply. ACSM is more biased toward medium-chain fatty acid oxidation and carboxylic acid metabolism. ACSL partitions long-chain fatty acids among oxidation, storage, and membrane lipid remodeling. ACSVL/SLC27 is better suited for explaining very-long-chain fatty acids, fatty acid uptake, and complex lipid homeostasis.

For more related articles, please see below:

[1] Fatty Acids from Basics to Lab Practice: Structural Classification, Research Uses, and Selection Tips (with an Aladdin Representative Product Quick-Reference Table)